Cell therapy manufacturing. One patient, one chain of identity, one accountable journey.

Autologous cell therapy turns one patient's starting material into one patient's treatment. Manufacturing, quality, clinical scheduling, identity, custody, condition, and logistics therefore share the same critical path.

Seal connects the treatment order, collection, starting-material receipt, chain of identity, patient-specific electronic batch record, materials, equipment, process samples, release, cryogenic storage, shipment, treatment-center handoff, and later outcome while restricting protected data to authorized roles.

A therapy case begins with an authorized order or enrollment context, treatment center, product, collection requirements, planned dates, patient or donor identity token, and permitted clinical attributes.

The manufacturing order derives from that case but uses controlled pseudonymous identifiers in operational views. Schedule changes, eligibility holds, cancellation, recollection, and manufacturing disposition remain synchronized without exposing unnecessary patient information.

The identity service maintains the authorized relationship between patient, therapy case, collection, manufacturing, and final-product identifiers. Production users see the token and only the clinical attributes required for safe execution. Couriers, laboratories, quality reviewers, and treatment-center coordinators receive role-appropriate views.

At each critical handoff, the system verifies the expected identifier pair and physical object. It records whether verification used scan, electronic message, independent human check, or approved alternate method. Printing, relabeling, identifier replacement, and manual recovery require a controlled reason and preserve prior values.

Access to protected identity, failed attempts, resolution, and changes remains audited. Reports and analytics use pseudonymous case data unless identified information is explicitly required and authorized.

Chain of identity connects the authorized patient identity to collected material, every in-process container and sample, final product, shipment, receipt, and administration handoff. It is not a single barcode field.

Each identity event records identifiers presented, source and destination objects, user or system, place, time, verification method, result, and exception state. Dual verification or electronic reconciliation follows the approved risk model. A mismatch blocks normal progression and initiates containment.

Collection, courier pickup, site receipt, internal handoffs, cleanroom transfer, storage, QC sampling, final pack-out, courier movement, treatment-center receipt, and clinical handoff form a custody chain.

Seal records sender, receiver, timestamp, location, container, seal or condition, required documents, acknowledgement, and unresolved discrepancy. A planned shipment is not treated as received, and a scan is not treated as custody acceptance without the configured confirmation.

Collection slots, courier lanes, manufacturing suites, equipment, qualified staff, material availability, QC capacity, release windows, cryogenic storage, treatment-center readiness, and product shelf life determine feasibility.

Seal shows dependencies and committed windows around the therapy case. Replanning preserves the original schedule, reason, approvals, downstream acknowledgements, and clinical impact. A delay can propagate to collection, production, shipment, lymphodepletion or other treatment preparation without silent divergence.

Receipt verifies identity, custody, collection time, container, seals, temperature or condition history, quantity, cell count or other required attributes, documents, and acceptance criteria. Quarantine remains explicit until review.

Nonconforming or borderline material follows the approved medical and quality decision path. A concession does not overwrite the observed state. Recollection, rescue processing, continued manufacture, or cancellation retain accountable rationale and patient impact.

Starting-material quantity and quality vary. The approved process can use decision tables, calculations, ranges, branches, repeat operations, sampling, and timing rules to adapt without free-form improvisation.

Each executed branch records the source condition, governing rule, calculation, selected path, user, and outcome. Changes outside the approved design become deviations or authorized exceptions. The final record shows both the common platform process and patient-specific course.

Media, cytokines, beads, vectors, reagents, disposables, bags, tubing, filters, labels, and cryopreservation materials are verified at use. Lot, status, expiry, quantity, storage, and supplier remain connected to the therapy case.

Closed and functionally closed assemblies carry component positions, connection events, integrity checks, use windows, and disposal. A material or component concern can trace forward to every affected patient-specific lot while preserving access controls.

Equipment qualification, calibration, maintenance, cleaning, software, location, and availability are checked at the step. Personnel need current procedure, aseptic, equipment, task, and practical qualification.

If a qualification or equipment condition later becomes unacceptable, impact assessment identifies therapy cases processed since the last known acceptable state.

Cell count, viability, phenotype, purity, potency-related measures, microbiology, vector copy or other product-specific tests can gate expansion, harvest, formulation, cryopreservation, and release.

The process step creates the sample with source container, time, priority, test panel, method, limits, and waiting decision attached. Results return without transcription and preserve raw-data references, calculations, review, invalidity, OOS, and approved adjustment.

Every transfer identifies source and destination containers, quantities, units, time, operator, equipment, and resulting state. Sampling and discard are genealogy events, not untracked reductions.

Reconciliation follows cells, volume, containers, and critical consumables at the level meaningful to the process. A missing aliquot or unexpected loss identifies the physical population and blocks closure until resolved.

Controlled-rate freezing, cryopreservation formulation, container identity, freezer program, process data, storage location, temperature evidence, transfers, and excursions remain attached to the final product.

Shipment pack-out identifies shipper, coolant or dry shipper state, logger, conditioning, product container, custody seals, route, expected duration, and recovery plan. Condition data and receipt acknowledgement return to the therapy case.

Disposition evaluates complete execution, identity and custody, materials, equipment, environmental evidence, laboratory results, deviations, reconciliation, container state, labeling, storage, and shipment readiness.

Conditional, exceptional, or out-of-specification pathways—where applicable and authorized—retain clinical and quality roles, evidence available, rationale, patient-specific benefit-risk decision, conditions, notifications, and follow-up. Pending never appears as passed.

The label renders from approved product, therapy case, patient or donor identifiers permitted for the role, collection and manufacturing identifiers, container, storage, expiry, and administration instructions.

Scans verify physical container and destination. Reprints preserve prior output and reason. Operations can confirm identity without displaying unnecessary clinical data; access and audit history remain role based.

Dispatch checks released state, destination, treatment schedule, shipper preparation, route, courier, documentation, identifiers, and contingency. Milestones and exceptions remain visible to manufacturing and authorized clinical coordination.

Treatment-center receipt records time, condition, identifiers, seal, storage, receiver, and discrepancy. The clinical handoff confirms the product reached the authorized patient workflow; Seal does not replace clinical administration systems or medical judgment.

Collection delay, identity discrepancy, insufficient starting material, contamination concern, growth failure, missed process window, equipment outage, failed test, cryogenic excursion, courier delay, or treatment reschedule requires a coordinated response.

The event opens with therapy case, physical material, schedule, evidence, responsible parties, and remaining windows attached. Actions and communications are time-stamped and acknowledged. Contingency can include holds, alternative equipment, recollection, rescue, reroute, or cancellation according to the approved process.

Treatment center, collection site, courier, sponsor, manufacturing site, testing laboratory, quality unit, storage provider, and clinical team may act in different systems. A status email is not enough when a delay or discrepancy can change patient care.

Seal records the message or event type, authoritative source, intended recipients, time sent, acknowledgement, response due, attachment or evidence, and escalation. Milestones distinguish planned, dispatched, received, accepted, completed, failed, and cancelled states.

Communication templates can protect privacy while still conveying actionable information. An identity discrepancy, manufacturing delay, release condition, or shipment excursion stays open until the required party acknowledges the updated state and the downstream schedule is reconciled.

The first implementation should follow one representative patient from order through scheduling, collection, receipt, identity and custody, dynamic manufacturing, samples and results, cryopreservation, release, labeling, shipment, treatment-center receipt, and reconciliation.

Include an identity mismatch, schedule change, borderline receipt, process branch, missing result, equipment outage, cryogenic excursion, courier delay, and cancellation or recollection. The system is ready when every handoff preserves identity, state, time, and accountable decision.